Raloxifen 60 - Pharmaceutical Grade

Raloxifene is a benzothiophene-based selective estrogen receptor modulator (SERM) with tissue-specific effects, acting as an anti-estrogen in breast tissue and as an estrogen in bone. Approved in the U.S. in 1997, it was initially prescribed for osteoporosis and later for breast cancer prevention in high-risk postmenopausal women. Known commercially as Evista, it is marketed globally. In male users, raloxifene has been studied for managing gynecomastia and modulating testosterone and IGF-1, offering possible benefits during post-cycle therapy.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Raloxifen 60 by Pharmaceutical Grade, consult with your doctor or healthcare professional.